Latest Breaking News On - Tiumbio kosdaq - Page 1 : comparemela.com

TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

/PRNewswire/ TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics.

United statesSouth koreaKyonggi doTiumbio kosdaqHun taek kimSuna choJunseok jangCorporate communications investor relationsTiumbio co ltdAmerican society of clinical oncologyPrnewswire tiumbio co ltdHead of corporate communications investor relationsClinical oncologyCorporate communications

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaKyonggi doTiumbio kosdaqSuna choJunseok jangCorporate communications investor relationsInternational society on thrombosisPrnewswire tiumbio co ltdHead of corporate communications investor relationsNovo nordiskItalian medicines agencySpanish agency of medicinesTiumbio co ltdClinical trialLong acting recombinant activated factor